289 related articles for article (PubMed ID: 24947256)
21. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
[TBL] [Abstract][Full Text] [Related]
22. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Bello C; Veliz M; Pinilla-Ibarz J
Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
[TBL] [Abstract][Full Text] [Related]
24. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.
Dupuis J; Brice P; François S; Ysebaert L; de Guibert S; Levy V; Leprêtre S; Choquet S; Dilhuydy MS; Fornecker L; Morel V; Tempescul A
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):e43-6. PubMed ID: 25193089
[TBL] [Abstract][Full Text] [Related]
25. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
26. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
27. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
[TBL] [Abstract][Full Text] [Related]
28. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
[TBL] [Abstract][Full Text] [Related]
29. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Österborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJ
Br J Haematol; 2015 Jul; 170(1):40-9. PubMed ID: 25825041
[TBL] [Abstract][Full Text] [Related]
30. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab (Arzerra) for CLL.
Med Lett Drugs Ther; 2010 Jun; 52(1341):51-2. PubMed ID: 20585286
[No Abstract] [Full Text] [Related]
32. Monoclonal antibody therapy of chronic lymphocytic leukaemia.
Cheson BD
Best Pract Res Clin Haematol; 2010 Mar; 23(1):133-43. PubMed ID: 20620977
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
34. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
35. Ofatumumab: chronic lymphocytic leukaemia: a last resort.
Prescrire Int; 2010 Oct; 19(109):201-3. PubMed ID: 21180369
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the effect of ofatumumab on cardiac repolarization.
Jewell RC; Laubscher K; Lewis E; Fang L; Gafoor Z; Carey J; McKeown A; West S; Wright O; Sedoti D; Dixon I; Hottenstein CS; Chan G
J Clin Pharmacol; 2015 Jan; 55(1):114-21. PubMed ID: 25103870
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.
Wu Y; Wang Y; Gu Y; Xia J; Kong X; Qian Q; Hong Y
Hematology; 2017 Dec; 22(10):578-584. PubMed ID: 28580841
[TBL] [Abstract][Full Text] [Related]
38. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]